Mutations and expression profiles of DDR genes have recently been associated with alterations in immune regulatory gene expression and CD8-positive T cell infiltration in the tumor microenvironment, serving as a predictive marker of immune checkpoint blockade (ICB) therapy efficiency56,57. The gene discussed is CD8A; the disease is neoplasm.